BMY - Bristol-Myers Squibb Company
| Previous Close | 45.80 |
| Open | 46.05 |
| Bid | 45.48 x 3200 |
| Ask | 45.60 x 4000 |
| Day's Range | 45.03 - 46.13 |
| 52 Week Range | 44.30 - 63.69 |
| Volume | 23,488,951 |
| Avg. Volume | 18,850,864 |
| Market Cap | 74.378B |
| Beta (3Y Monthly) | 0.87 |
| PE Ratio (TTM) | 15.12 |
| EPS (TTM) | 3.01 |
| Earnings Date | Apr 25, 2019 |
| Forward Dividend & Yield | 1.64 (3.44%) |
| Ex-Dividend Date | 2019-04-04 |
| 1y Target Est | 57.80 |
- Motley Fool•4 hours ago
How Marijuana Legalization Affected OrganiGram and Aphria's Latest Results
These two marijuana stocks reported very different results last quarter. Plus, how Abbott's challenging Dexcom in diabetes, and what's next for Bristol-Myers following its Celgene acquisition.
- Motley Fool•13 hours ago
3 Cancer Treatment Stocks to Buy in April
These three cancer stocks have tremendous upside potential.
- Motley Fool•yesterday
5 Top Healthcare Stocks to Buy in 2019
Healthcare is hot, and these top healthcare stocks could be among the hottest of them all this year.
- Zacks•2 days ago
Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Moody's•3 days ago
Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's exchange notes; under review for downgrade
Moody's Investors Service ("Moody's") assigned an A2 rating to Bristol-Myers Squibb Company's ("Bristol") proposed new senior unsecured exchange note offering. The rating is under review for downgrade. There are no changes to Bristol's existing ratings including the A2 senior unsecured long-term rating or the Prime-1 short-term rating, and these ratings remain under review for downgrade.
- Simply Wall St.•3 days ago
Bristol-Myers Squibb Company (NYSE:BMY): Immense Growth Potential?
Looking at Bristol-Myers Squibb Company's (NYSE:BMY) earnings update in December 2018, analyst consensus outlook appear cautiously optimistic, with earnings expected to grow by...
- Business Wire•3 days ago
Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes
Bristol-Myers Squibb Company announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation , of an exchange offer for any and all outstanding notes issued by Celgene for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb and cash.
- Zacks•4 days ago
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
Key highlights of the past week are collaborations and pipeline updates.
GuruFocus.com•4 days agoBill Nygren Buys Constellation, S&P Global, Sells 5 in 1st Quarter
Bill Nygren (Trades, Portfolio), portfolio manager of the Oakmark Fund, started two positions and exited five in the first quarter, he said ahead of Securities and Exchange Commission deadlines for portfolio disclosure. Warning! GuruFocus has detected 3 Warning Sign with STZ. In a first-quarter letter released last week, Nygren discussed purchases of Constellation Brands (STZ) and S&P Global Inc. (SPGI).
- Zacks•4 days ago
Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $46.02, marking a -1.03% move from the previous day.
- Motley Fool•5 days ago
Why Celgene Shareholders Should Hold On to Their Bristol-Myers Squibb Stock Once the Acquisition Closes
The fat lady is getting ready to sing with this big pharma deal. Celgene shareholders will soon have a decision to make.
- GuruFocus.com•5 days ago
52-Week Company Lows
According to GuruFocus' list of 52-week lows, these guru stocks have reached their 52-week lows. The price of UnitedHealth Group Inc. (UNH) shares has declined to close to the 52-week low of $223.22, which is 23.3% off the 52-week high of $287.94. The company has a market cap of $214.19 billion.
- Zacks•5 days ago
Bristol-Myers' Shareholders Vote for Celgene Acquisition
Bristol-Myers' (BMY) gets a green signal from a majority of its shareholders for the merger with Celgene Corporation.
- Zacks•5 days ago
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
- GuruFocus.com•6 days ago
Stocks That Fell to 3-Year Lows in the Week of April 12
Bristol-Myers Squibb Company (BMY), Annaly Capital Management Inc. (NLY), Newell Brands Inc. (NWL) and Mylan NV (MYL) have declined to their three-year lows. Bristol-Myers Squibb Company is an American international pharmaceutical company that manufactures prescription pharmaceuticals in various therapeutic areas including cancer, cardiovascular diseases, diabetes, hepatitis, and HIV. The trailing 12-month dividend yield of Bristol-Myers Squibb Company stocks is 3.53%.
- CNBC•8 days ago
Bristol-Myers CEO: We're 'one step closer to creating that great company' with Celgene
"When the two companies come together, we'll have two growing businesses," Caforio said in an interview with "Mad Money's" Jim Cramer. It's going to be a great company, [will] create value for shareholders, [and will be] very good for patients," he said. "I'm focused and we're focused on creating value for the long term and we're getting to work on the integration ... I believe the value of the new company will be demonstrated rapidly," he says.
- Reuters•8 days ago
Bristol-Myers says shareholders vote to approve Celgene takeover
By Michael Erman and Svea Herbst-Bayliss NEW YORK (Reuters) - Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion (56.6 billion pounds) acquisition of biotech Celgene Corp ...
- TheStreet.com•8 days ago
Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up
More than 75% of Bristol-Myers shareholders voted to approve the deal, according to a preliminary tally announced by Bristol-Myers on Friday. Bristol-Myers' position took a positive turn in late March after an influential shareholder advisory group recommended investors vote in favor of the cancer drug specialist's takeover, and a key activist dropped its opposition to the deal. Institutional Shareholder Services recommended the deal, which had been challenged by key Bristol-Myers shareholders Starboard Value and Wellington Management, ahead of Friday's vote.
- Business Wire•8 days ago
Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
Bristol-Myers Squibb Company (BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company’s pending merger with Celgene Corporation (CELG) at the Special Meeting of Stockholders. “We are pleased with the outcome of today’s Special Meeting and thank our shareholders for their support for this combination,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines.
- Zacks•8 days ago
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
- Financial Times•9 days ago
Bristol-Myers shareholders approve $90bn Celgene takeover
Celgene shareholders also gave their support for the deal, which is expected to close in the third quarter but awaits US regulatory approval. “Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines,” Bristol-Myers chairman and chief executive Giovanni Caforio said in a statement.
- CNBC Videos•4 days ago
Watch CNBC's exclusive interview with Starboard Value CEO Jeff Smith
Jeff Smith, Starboard Value CEO, sits down with CNBC's David Faber for an exclusive interview at the 13D Monitor Active-Passive Investor Summit.
- CNBC Videos•8 days ago
Bristol-Myers CEO: We're 'one step closer to creating that great company' with Celgene
Celgene brings to Bristol-Myers five late-stage products that could be approved in the near term, Caforio said.
- CNBC Videos•8 days ago
'One step closer to creating that great company' with Celgene, says Bristol-Myers CEO
Celgene brings to Bristol-Myers five late-stage products that could be approved in the near term, Caforio said.
